COMMUNIQUÉS West-GlobeNewswire
-
SHERPA research consortium initiates seven clinical studies to validate AI-based assistive technologies for minimally invasive brain and cancer treatments
03/03/2026 -
Quell Therapeutics Initiates CHILL Phase 1/2 Trial of Novel QEL-005 CAR-Treg Therapy in Refractory Rheumatoid Arthritis and Systemic Sclerosis Following UK CTA Approval
03/03/2026 -
Quell Therapeutics Demonstrates Safety, Phenotypic Stability, Durability and Early Efficacy with Phenotype‑Locked™ CAR‑Tregs in LIBERATE Phase 1/2 Liver Transplant Study
03/03/2026 -
Resmed’s Global Sleep Survey Reveals Sleep is One of the Top Health Priorities, but Quality Rest Remains Out of Reach
03/03/2026 -
Montis Biosciences Advances First-in-Class Dual-Action C1q Antibody with Strong Preclinical Proof-of-Concept in Neuroinflammatory Diseases
03/03/2026 -
AEON Clinic Introduces Exomind to Treat OCD ADHD PTSD And Other Complex Mental Health Conditions
03/03/2026 -
SNIPR announces Publication of Final Positive Phase 1 Results for SNIPR001 in The Lancet Microbe
03/03/2026 -
Fagron completes acquisition of Vepakum
03/03/2026 -
MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock
03/03/2026 -
Care@Home 4 Life Announces the Appointment of Industry Veteran Daniel Peters as Regional Sales Director
03/03/2026 -
Alignment Healthcare Announces Pricing of Secondary Offering
03/03/2026 -
BrightSpring Announces Pricing of Secondary Offering of Common Stock and Concurrent Share Repurchase
03/03/2026 -
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/03/2026 -
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
02/03/2026 -
Immuneering to Present at the Leerink Global Healthcare Conference
02/03/2026 -
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/03/2026 -
Cytokinetics to Participate in March Investor Conferences
02/03/2026 -
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
02/03/2026 -
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
02/03/2026
Pages